文献速递甲状腺疾病

分化型甲状腺癌复发的定义:一项系统综述

The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature.
PubMed 文献 · Thyroid · 2024-10-02

该系统综述检索2018年1月至2023年12月MEDLINE和EMBASE,纳入70项研究(69项回顾性研究、1项随机对照试验),评估分化型甲状腺癌复发的定义。结果显示各治疗类别(腺叶切除、全甲状腺切除±放射性碘)均无普遍接受的复发定义,仅9项研究(12.9%)区分复发与持续性疾病。

要点

  • 各治疗类别均无普遍接受的复发定义。
  • 腺叶切除后最常见定义为细胞学/病理学证实的复发(该亚组47.1%)。
  • 全甲状腺切除加放射性碘后最常见定义为细胞学/病理学证实的复发和/或影像学异常(该亚组22.4%)。

核心结论

  • 当前研究中所有治疗类别均无普遍接受的复发定义。
  • 该发现将为未来基于国际德尔菲法的提案提供基础,以建立普遍接受的复发定义。

研究设计与样本

  • 系统综述,遵循2020年PRISMA声明,方案注册于PROSPERO(CRD42021291753)。
  • 2023年12月检索MEDLINE和EMBASE,纳入2018年1月至2023年12月报告分化型甲状腺癌复发的研究。
  • 共纳入70项研究,包括69项回顾性研究和1项随机对照试验;患者中位数438例(范围25-2297)。
  • 17项研究(24.3%)报告腺叶切除,4项(5.7%)报告全甲状腺切除不加放射性碘,49项(70.0%)报告加放射性碘。

主要发现

  • 所有研究使用细胞学/病理学、影像学、甲状腺球蛋白(-抗体)和预定最短无肿瘤时间中的一种或组合定义复发。
  • 腺叶切除后最常见定义为细胞学/病理学证实的复发(该亚组47.1%)。
  • 全甲状腺切除加放射性碘后最常见定义为细胞学/病理学证实的复发和/或影像学异常(该亚组22.4%)。
  • 全甲状腺切除不加放射性碘后未发现一致定义。
  • 9项研究(12.9%)区分复发与持续性疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Recurrence is a key outcome to evaluate the treatment effect of differentiated thyroid carcinoma (DTC). However, no consistent definition of recurrence is available in current literature or international guidelines. Therefore, the primary aim of this systematic review was to delineate the definitions of recurrence of DTC, categorized by total thyroidectomy with radioactive iodine ablation (RAI), total thyroidectomy without RAI and lobectomy, to assess if there is a generally accepted definition among these categories. Methods: This study adhered to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. In December 2023, a systematic literature search in MEDLINE and EMBASE was performed for studies reporting on the recurrence of DTC, from January 2018 to December 2023. Studies that did not provide a definition were excluded. Primary outcome was the definition of recurrence of DTC. Secondary outcome was whether studies differentiated between recurrence and persistent disease. Two independent investigators screened the titles and abstracts, followed by full-text assessment and data extraction. The study protocol was registered in PROSPERO, CRD42021291753. Results: In total, 1450 studies were identified. Seventy studies met the inclusion criteria, including 69 retrospective studies and 1 randomised controlled trial (RCT). Median number of patients in the included studies was 438 (range 25-2297). In total, 17 studies (24.3%) reported on lobectomy, 4 studies (5.7%) on total thyroidectomy without RAI, and 49 studies (70.0%) with RAI. All studies defined recurrence using one or a combination of four diagnostic modalities cytology/pathology, imaging studies, thyroglobulin (-antibodies), and a predetermined minimum tumor-free time span. The most common definition of recurrence following lobectomy was cytology/pathology-proven recurrence (47.1% of this subgroup), following total thyroidectomy with RAI was cytology/pathology-proven recurrence and/or anomalies detected on imaging studies (22.4% of this subgroup). No consistent definition was found following total thyroidectomy without RAI. Nine studies (12.9%) differentiated between recurrence and persistent disease. Conclusion: Our main finding is that there is no universally accepted definition for recurrence of DTC in the current studies across any of the treatment categories. The findings of this study will provide the basis for a future, international Delphi-based proposal to establish a universally accepted definition of recurrence of DTC. A uniform definition could facilitate global discussion and enhance the assessment of treatment outcomes regarding recurrence of DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. van de Berg DJ, Rodriguez Schaap PM, Jamaludin FS, et al. The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature. Thyroid. 2024. PMID: 39283824. doi:10.1089/thy.2024.0271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。